001454509 000__ 05417cam\a22005297a\4500
001454509 001__ 1454509
001454509 003__ OCoLC
001454509 005__ 20230314003216.0
001454509 006__ m\\\\\o\\d\\\\\\\\
001454509 007__ cr\un\nnnunnun
001454509 008__ 230215s2023\\\\si\\\\\\o\\\\\000\0\eng\d
001454509 019__ $$a1369517376$$a1369663607
001454509 020__ $$a9789811953996$$q(electronic bk.)
001454509 020__ $$a9811953996$$q(electronic bk.)
001454509 020__ $$z9811953988
001454509 020__ $$z9789811953989
001454509 0247_ $$a10.1007/978-981-19-5399-6$$2doi
001454509 035__ $$aSP(OCoLC)1369509432
001454509 040__ $$aYDX$$beng$$cYDX$$dGW5XE$$dEBLCP
001454509 049__ $$aISEA
001454509 050_4 $$aRM301.25
001454509 08204 $$a615.1/9$$223/eng/20230215
001454509 24500 $$aDrug repurposing for emerging infectious diseases and cancer /$$cRanbir Chander Sobti, Sunil K. Lal, Ramesh K. Goyal, editors.
001454509 260__ $$aSingapore :$$bSpringer,$$c2023.
001454509 300__ $$a1 online resource
001454509 5050_ $$aIntro -- Preface -- Contents -- Editors and Contributors -- Chapter 1: Drug Repurposing: An Advance Way to Traditional Drug Discovery -- 1.1 Introduction -- 1.2 Rationale of Drug Repurposing -- 1.3 Role of Drug Repurposing in Conventional Pharmaceutical Market -- 1.4 Roadmap to Modern Drug Repurposing -- 1.5 Drug Repurposing Strategies and Approaches -- 1.5.1 Computational Approaches -- 1.5.2 Experimental Approaches -- 1.6 Opportunity and Challenges in Drug Repurposing -- 1.7 Conclusion -- References -- Chapter 2: Drug Polypharmacology Toward Drug Repurposing -- 2.1 Drug Pharmacology
001454509 5058_ $$a2.2 Drug Repurposing -- 2.3 Need for Drug Repurposing -- 2.4 Challenges of Drug Repurposing -- 2.5 Different Strategies of Drug Repurposing -- 2.6 Methodology for Drug Repurposing -- 2.6.1 Virtual Screening -- 2.6.2 Structure Prediction of Target -- 2.7 Chemical Composition of Drug -- 2.8 Prediction of Protein Binding Site -- 2.9 Successful Example of Drug Repurposing -- References -- Chapter 3: Pharmacovigilance-Based Drug Repurposing -- 3.1 Drug Development and Pharmacovigilance -- 3.1.1 Need for Pharmacovigilance -- 3.2 Pharmacovigilance and Drug Repurposing -- 3.2.1 Serendipity
001454509 5058_ $$a3.2.2 Signature Matching -- 3.2.3 Mechanistic Profiling -- 3.2.4 Inverse Signals -- 3.2.4.1 Signal -- 3.2.4.1.1 Inverse Signal -- 3.3 The Process of Drug Repurposing -- 3.3.1 Present Scenario -- 3.3.1.1 Alzheimerś Disease -- 3.3.1.2 Raynaudś Phenomenon (RP) -- 3.3.1.3 COVID-19 -- 3.4 Future Perspectives -- Further Reading -- Chapter 4: In Silico Analysis of Cellular Interactors of PQBP1 for Potential Drug Repurposing -- 4.1 Introduction -- 4.2 Material and Methods -- 4.3 Results and Discussion -- References -- Chapter 5: Drug Repurposing Opportunities in Cancer -- 5.1 Introduction
001454509 5058_ $$a5.2 Drug Repurposing -- 5.3 Drug Repurposing Barriers -- 5.4 Computational Approaches in Drug Repurposing -- 5.5 Drug Repurposing in Cancer -- 5.5.1 Importance of Drug Repurposing in Cancer Treatment -- 5.5.2 Repurposing Small-Molecule Non-Oncology Drugs -- 5.5.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) -- 5.5.2.1.1 Aspirin -- 5.5.2.1.2 Diclofenac -- 5.5.2.1.3 Ibuprofen -- 5.5.2.1.4 Naproxen -- 5.5.2.2 Statins -- 5.5.2.2.1 Simvastatin -- 5.5.2.3 Antidiabetic Drugs -- 5.5.2.3.1 Metformin -- 5.5.2.3.2 Phenformin -- 5.5.2.4 Selective Estrogen Receptor Modulators (SERMs)
001454509 5058_ $$a5.5.2.4.1 Raloxifene -- 5.5.2.5 Antidepressants -- 5.5.2.5.1 Imipramine -- 5.5.2.5.2 Trifluoperazine -- 5.5.2.5.3 Fluoxetine -- 5.5.2.6 Antipsychotic -- 5.5.2.6.1 Chlorpromazine -- 5.5.2.7 Anticonvulsant -- 5.5.2.7.1 Valproic Acid -- 5.5.2.8 Antiviral Drugs -- 5.5.2.8.1 Ritonavir -- 5.5.2.8.2 Nelfinavir -- 5.5.2.8.3 Lopinavir -- 5.5.2.9 Antibiotics -- 5.5.2.9.1 Ciprofloxacin -- 5.5.2.9.2 Nifuroxazide -- 5.5.2.9.3 Moxifloxacin -- 5.5.2.10 Antifungals -- 5.5.2.10.1 Clotrimazole -- 5.5.2.10.2 Itraconazole -- 5.5.2.11 Antiepileptic Drug -- 5.5.2.11.1 Flunarizine -- 5.5.2.11.2 Prazosin
001454509 506__ $$aAccess limited to authorized users.
001454509 520__ $$aThis book presents drug repurposing strategies to combat infectious diseases and cancer. It discusses key experimental and in silico approaches for modern drug repositioning, including signature matching, molecular docking, genome-wide associated studies, and network-based approaches aided by artificial intelligence. Further, the book presents various computational and experimental strategies for better understanding disease mechanisms and identify repurposed drug candidates for personalized pharmacotherapy. It also explores the databases for drug repositioning, summarizes the approaches taken for drug repositioning, and highlights and compares their characteristics and challenges. Towards the end, the book discusses challenges and limitations encountered in computational drug repositioning.
001454509 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed February 15, 2023).
001454509 650_0 $$aDrug development.
001454509 650_0 $$aCommunicable diseases$$xChemotherapy.
001454509 650_0 $$aCancer$$xChemotherapy.
001454509 655_0 $$aElectronic books.
001454509 7001_ $$aSobti, R. C.
001454509 7001_ $$aLal, Sunil K.
001454509 7001_ $$aGoyal, Ramesh K.
001454509 77608 $$iPrint version: $$z9811953988$$z9789811953989$$w(OCoLC)1334722384
001454509 852__ $$bebk
001454509 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-981-19-5399-6$$zOnline Access$$91397441.1
001454509 909CO $$ooai:library.usi.edu:1454509$$pGLOBAL_SET
001454509 980__ $$aBIB
001454509 980__ $$aEBOOK
001454509 982__ $$aEbook
001454509 983__ $$aOnline
001454509 994__ $$a92$$bISE